Deglutition Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
![](/report_cover/2534/deglutition-disorders-market-epidemiology-industry-trends-share-size-growth-opportunity-n-forecast-2024-2034_en.gif)
The 7 major deglutition disorders markets are expected to exhibit a CAGR of 4.1% during 2024-2034.
The deglutition disorders market has been comprehensively analyzed in IMARC's new report titled "Deglutition Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Deglutition disorders, also known as dysphagia, refer to difficulties or abnormalities in the process of swallowing food or liquids. Some of the common symptoms include experiencing pain or discomfort while swallowing, coughing or choking during or after eating or drinking, regurgitation of food, unintended weight loss, etc. Individuals suffering from the ailment may also exhibit changes in their eating habits, such as avoiding certain foods or liquids, taking longer to finish meals, showing signs of aspiration pneumonia (e.g., recurrent chest infections), etc. The diagnosis of deglutition disorders involves a comprehensive evaluation by healthcare professionals, typically including speech-language pathologists, gastroenterologists, and sometimes neurologists. The diagnostic process often begins with a detailed medical history and a discussion of the patient's symptoms and eating difficulties. Various other procedures, such as fiberoptic endoscopic evaluation of swallowing (FEES) and videofluoroscopic swallowing study (VFSS), are also performed, allowing real-time visualization of the swallowing process to identify any abnormalities. High-resolution manometry may be used to assess esophageal motility. Additionally, a modified barium swallow study may be conducted to determine the safety and efficacy of swallowing different consistencies of food and liquids.
The increasing cases of various neurological conditions, such as Parkinson's disease, multiple sclerosis, muscular dystrophy, etc., that can affect the coordination and strength of the swallowing muscles are primarily driving the deglutition disorders market. Besides this, the rising incidences of several associated risk factors, including anatomical abnormalities in the throat, esophagus, or upper gastrointestinal tract, uncontrolled contractions of the pharynx, post-surgical complications, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of numerous anticholinergic medications, such as atropine, glycopyrrolate, scopolamine, etc., for regulating nerve impulses and improving swallowing function in patients is further bolstering the market growth. Apart from this, the inflating application of dysphagia therapy, which involves exercises and techniques to enhance the strength of the swallowing muscles as well as reduce the risk of aspiration, is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in customized swallowing devices, including the introduction of intraoral prosthetics and tongue depressors, that can optimize swallowing mechanics and support the coordination of oral and pharyngeal phases are expected to drive the deglutition disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the deglutition disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for deglutition disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the deglutition disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the deglutition disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the deglutition disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current deglutition disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the deglutition disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the deglutition disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the deglutition disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of deglutition disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of deglutition disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of deglutition disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with deglutition disorders across the seven major markets?
What is the size of the deglutition disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of deglutition disorders?
What will be the growth rate of patients across the seven major markets?
Deglutition Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for deglutition disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the deglutition disorders market?
What are the key regulatory events related to the deglutition disorders market?
What is the structure of clinical trial landscape by status related to the deglutition disorders market?
What is the structure of clinical trial landscape by phase related to the deglutition disorders market?
What is the structure of clinical trial landscape by route of administration related to the deglutition disorders market?
The deglutition disorders market has been comprehensively analyzed in IMARC's new report titled "Deglutition Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Deglutition disorders, also known as dysphagia, refer to difficulties or abnormalities in the process of swallowing food or liquids. Some of the common symptoms include experiencing pain or discomfort while swallowing, coughing or choking during or after eating or drinking, regurgitation of food, unintended weight loss, etc. Individuals suffering from the ailment may also exhibit changes in their eating habits, such as avoiding certain foods or liquids, taking longer to finish meals, showing signs of aspiration pneumonia (e.g., recurrent chest infections), etc. The diagnosis of deglutition disorders involves a comprehensive evaluation by healthcare professionals, typically including speech-language pathologists, gastroenterologists, and sometimes neurologists. The diagnostic process often begins with a detailed medical history and a discussion of the patient's symptoms and eating difficulties. Various other procedures, such as fiberoptic endoscopic evaluation of swallowing (FEES) and videofluoroscopic swallowing study (VFSS), are also performed, allowing real-time visualization of the swallowing process to identify any abnormalities. High-resolution manometry may be used to assess esophageal motility. Additionally, a modified barium swallow study may be conducted to determine the safety and efficacy of swallowing different consistencies of food and liquids.
The increasing cases of various neurological conditions, such as Parkinson's disease, multiple sclerosis, muscular dystrophy, etc., that can affect the coordination and strength of the swallowing muscles are primarily driving the deglutition disorders market. Besides this, the rising incidences of several associated risk factors, including anatomical abnormalities in the throat, esophagus, or upper gastrointestinal tract, uncontrolled contractions of the pharynx, post-surgical complications, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of numerous anticholinergic medications, such as atropine, glycopyrrolate, scopolamine, etc., for regulating nerve impulses and improving swallowing function in patients is further bolstering the market growth. Apart from this, the inflating application of dysphagia therapy, which involves exercises and techniques to enhance the strength of the swallowing muscles as well as reduce the risk of aspiration, is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in customized swallowing devices, including the introduction of intraoral prosthetics and tongue depressors, that can optimize swallowing mechanics and support the coordination of oral and pharyngeal phases are expected to drive the deglutition disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the deglutition disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for deglutition disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the deglutition disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the deglutition disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the deglutition disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current deglutition disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the deglutition disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the deglutition disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the deglutition disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of deglutition disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of deglutition disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of deglutition disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with deglutition disorders across the seven major markets?
What is the size of the deglutition disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of deglutition disorders?
What will be the growth rate of patients across the seven major markets?
Deglutition Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for deglutition disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the deglutition disorders market?
What are the key regulatory events related to the deglutition disorders market?
What is the structure of clinical trial landscape by status related to the deglutition disorders market?
What is the structure of clinical trial landscape by phase related to the deglutition disorders market?
What is the structure of clinical trial landscape by route of administration related to the deglutition disorders market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DEGLUTITION DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DEGLUTITION DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DEGLUTITION DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DEGLUTITION DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DEGLUTITION DISORDERS - UNMET NEEDS
10 DEGLUTITION DISORDERS - KEY ENDPOINTS OF TREATMENT
11 DEGLUTITION DISORDERS - MARKETED PRODUCTS
11.1 List of Deglutition Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DEGLUTITION DISORDERS - PIPELINE DRUGS
12.1 List of Deglutition Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. DEGLUTITION DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DEGLUTITION DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DEGLUTITION DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Deglutition Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Deglutition Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Deglutition Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Deglutition Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Deglutition Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Deglutition Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Deglutition Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Deglutition Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Deglutition Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Deglutition Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Deglutition Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Deglutition Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Deglutition Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Deglutition Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Deglutition Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Deglutition Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Deglutition Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Deglutition Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Deglutition Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Deglutition Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Deglutition Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Deglutition Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Deglutition Disorders - Access and Reimbursement Overview
16 DEGLUTITION DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DEGLUTITION DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DEGLUTITION DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DEGLUTITION DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DEGLUTITION DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DEGLUTITION DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DEGLUTITION DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DEGLUTITION DISORDERS - UNMET NEEDS
10 DEGLUTITION DISORDERS - KEY ENDPOINTS OF TREATMENT
11 DEGLUTITION DISORDERS - MARKETED PRODUCTS
11.1 List of Deglutition Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DEGLUTITION DISORDERS - PIPELINE DRUGS
12.1 List of Deglutition Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. DEGLUTITION DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DEGLUTITION DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DEGLUTITION DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Deglutition Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Deglutition Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Deglutition Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Deglutition Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Deglutition Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Deglutition Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Deglutition Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Deglutition Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Deglutition Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Deglutition Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Deglutition Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Deglutition Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Deglutition Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Deglutition Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Deglutition Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Deglutition Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Deglutition Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Deglutition Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Deglutition Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Deglutition Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Deglutition Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Deglutition Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Deglutition Disorders - Access and Reimbursement Overview
16 DEGLUTITION DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DEGLUTITION DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DEGLUTITION DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX